294
Views
24
CrossRef citations to date
0
Altmetric
Original Investigations

Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients

, , , &
Pages 420-425 | Received 30 Apr 2007, Published online: 08 Dec 2009

References

  • Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(Suppl 7)22–31
  • Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New Engl J Med 1991; 324: 746–754
  • Beasley CM, Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58(Suppl 10)13–17
  • Benotti PN, Bistrian B, Benotti JR, Blackburn G, Forse RA. Heart disease and hypertension in severe obesity. The benefist of weight reduction. Am J Clin Nutr 1992; 55(Suppl 2)586–590
  • Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58(Suppl 10)55–62
  • Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J Am Med Assoc 2003; 289: 2560–2572
  • Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Br J Psychiatry 2001; 179: 167–171
  • Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry 2000; 61(Suppl 8)26–29
  • Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry 2002; 63(Suppl 9)5–11
  • Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951; 41: 279–286
  • Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989; 8: 691–709
  • Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001; 101: 277–288
  • George TP, Winther LC. Hypertension after initiation of clozapine [letter]. Am J Psychiatry 1996; 153: 1368–1369
  • Gupta S, Rajaprabhakaran R. Paradoxical hypertension associated with clozapine [letter]. Am J Psychiatry 1994; 151: 148
  • Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11–53
  • Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006; 16(Suppl 3)149–155
  • Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: A chart review of 82 patients. J Clin Psychiatry 2004; 65: 686–689
  • Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascualr disease. Am Heart J 2005; 150: 1115–1121
  • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796
  • Lambert, B, Tafesse, E, Carson, WH, Jr. 2003. Antipsychotic-induced hyperlipidemia among people with schizophrenia. Presented at the 156th annual meeting of the American Psychiatric Association; San Fransisco, CA.
  • Liebermann JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 2001; 62(Suppl 7)22–31
  • Littrell K, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J Clin Psychiatry 2000; 61: 912–915
  • Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172–1176
  • Meltzer HY. Atypical antipsychotic drugs. Psychopharmacology: The fourth generation of progress, FE Bloom, DJ Kupfer. Raven Press, New York 1995; 1277–1286
  • Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. J Am Med Assoc 2004; 291: 1238–1245
  • Mueck-Weymann M, Acker J, Agelink MW. Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. Psychopharmacology 2001; 154: 368–372
  • Naber D, Hippius H. The European experience with clozapine. Hosp Comm Psychiatry 1990; 41: 886–890
  • Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58: 45–49
  • Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176–185
  • Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29–39
  • Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537–551
  • Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71: 239–257
  • Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60(Suppl 21)16–19
  • Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. J Am Med Assoc 1978; 240: 1607–1610

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.